Under construction – not a live service
Sign in
Not yet taking people in ArgentinaPhase 2

Tests LY4086940 for weight management in adults with obesity or overweight

Tests LY4086940 against placebo in adults with obesity or overweight.

Plain-language title generated from the registry record
Registry title: A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes

Key facts

Where
Buenos Aires and Rosario, ArgentinaSee the 7 sites
Phase
Phase 2

AI summary: who the study is looking for

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with obesity, or with overweight and a weight-related health condition, who do not have type 2 diabetes. It compares LY4086940 with placebo.

Age
18 to 75 years
Sex
All sexes can join.
Disease stage
Obesity, or overweight with a weight-related health condition; no type 2 diabetes.
Earlier treatment
People who took medicines or remedies that promote weight loss in the 6 months before screening cannot join.

Main reasons for not taking part

  • Any prior diagnosis of type 2 diabetes, type 1 diabetes or rare forms of diabetes (gestational diabetes is allowed)
  • A lab value suggesting diabetes
  • Heart attack, stroke, unstable angina or hospital stay for heart failure in the 6 months before screening
  • Personal or family history (first-degree relative) of multiple endocrine neoplasia type 2A or 2B, thyroid C-cell hyperplasia or medullary thyroid carcinoma
  • Weight-loss medicines or remedies, including supplements, in the 6 months before screening

Read by machine on 12 November 2026.

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 75 years old?

Source: NCT07890376, who can take part

Where in Argentina

  • CARDIAMET Investigaciones MédicasBuenos Aires, ArgentinaContact: Angela Romero Zarante (principal investigator)No longer taking part
  • Centro de Investigaciones Metabólicas (CINME)Buenos Aires, ArgentinaContact: Federico Perez Manghi (principal investigator)No longer taking part
  • Centro Medico Dra. Laura Maffei- Investigacion Clinica AplicadaBuenos Aires, ArgentinaContact: Evelyn Blanc (principal investigator)No longer taking part
  • Centro Médico ViamonteBuenos Aires, ArgentinaContact: Diego Aizenberg (principal investigator)No longer taking part
  • Cicemo SrlBuenos Aires, ArgentinaContact: Pablo Costanzo (principal investigator)No longer taking part
  • Mautalen Salud e InvestigaciónBuenos Aires, ArgentinaContact: Jose Fretes (principal investigator)No longer taking part
  • Instituto Médico Catamarca IMECRosario, ArgentinaContact: Natacha Maldonado (principal investigator)No longer taking part

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Trial details

Who runs it
Eli Lilly and Company
Trial code
NCT07890376
Record updated
3 November 2026
Original description
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition.Read full original descriptionShow less

A Phase 2, Parallel-Group, Double-Blind Study to Investigate Weight Management With LY4086940 Compared With Placebo in Adult Participants With Obesity or Overweight and Without Type 2 Diabetes

The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who have overweight with a weight-related health condition.

Participation in the study will last about 58 weeks.

Inclusion: Meet inclusion criteria under Master Protocol CWMM (NCT06143956).

Exclusion: Have any prior diagnosis of type 2 diabetes, type 1 diabetes, or rare forms of diabetes mellitus, except gestational diabetes; Have any of the following cardiovascular conditions within 6 months prior to screening:; acute myocardial infarction; cerebrovascular accident (stroke); unstable angina, or; hospitalization due to congestive heart failure; Within 6 months prior to screening, have taken medications (prescribed or over the counter) or alternative remedies (including herbal or nutritional supplements) that promote weight loss; Have a laboratory value suggestive of diabetes; In addition to exclusion criteria under Master Protocol CWMM (NCT06143956); Have a known personal or family history (first-degree relative) of multiple endocrine neoplasia type 2A or 2B, thyroid C-cell hyperplasia, or medullary thyroid carcinoma.

ClinicalTrials.gov NCT07890376